Welcome to our dedicated page for Centessa Pharmaceuticals plc American Depositary Shares news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals plc American Depositary Shares stock.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is a next-generation biopharmaceutical company based in Cambridge, Massachusetts, dedicated to transforming the traditional drug development model. By leveraging an asset-centric R&D approach at scale, Centessa is advancing a robust pipeline of highly validated programs led by industry-leading teams. Each program is managed by a Centessa subsidiary and supported by a centralized infrastructure and executive management team.
The company’s clinical-stage assets include:
- SerpinPC - A novel treatment for Hemophilia A and B, currently in Phase 2b trials. SerpinPC is a subcutaneously administered inhibitor of APC, aiming to provide effective treatment irrespective of severity or inhibitor status.
- LB101 - A cutting-edge PD-L1xCD47 LockBody, targeting solid tumors. LB101 is currently in a Phase 1/2a clinical trial, designed to selectively drive potent effector functions to the tumor micro-environment while minimizing systemic toxicity.
- ORX750 - An orally administered, highly selective orexin receptor 2 (OX2R) agonist for Narcolepsy Type 1 (NT1) and other sleep disorders, currently in its Phase 1 clinical study.
- MGX292 - Targeting Pulmonary Arterial Hypertension (PAH).
- Undisclosed programs targeting solid tumors.
Recent Achievements include:
- Phase 2b study PRESent-3 of SerpinPC showing promising preliminary results.
- FDA Fast Track designation for SerpinPC in treating Hemophilia B.
- Progress in LB101's Phase 1/2a clinical trial.
- Launch of the Phase 1 study for ORX750, with initial proof-of-concept data in sleep-deprived healthy volunteers expected later this year.
Centessa’s innovative approach and comprehensive pipeline aim to deliver transformational medicines to patients, setting a new standard of care. For more information, visit their official website at http://www.centessa.com/.
Centessa Pharmaceuticals (Nasdaq: CNTA) has announced its participation in two upcoming investor conferences. The first event is the Jefferies London Healthcare Conference on November 17, 2022, featuring a fireside chat at 10:55 AM GMT. The second is the Evercore ISI HealthCONx Conference, held virtually on November 30, 2022, at 3:30 PM ET.
Live webcasts and archived recordings will be accessible on the Centessa Pharmaceuticals investor relations website.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that its oral orexin receptor 2 (OX2R) agonists showed potent efficacy in non-clinical models of narcolepsy type 1 (NT1). The findings will be presented at the Sleep Europe 2022 conference. The OX2R agonists demonstrated more than a thousand-fold selectivity for OX2R over OX1R and were effective in promoting wakefulness and reducing cataplexy in model mice. Centessa emphasizes its commitment to developing treatments for narcolepsy and acknowledges World Narcolepsy Day on September 22.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that the FDA has granted Orphan Drug Designation for its drug candidate SerpinPC, aimed at treating hemophilia B. Registrational studies are set to commence in 4Q 2022. SerpinPC, designed to enhance thrombin generation, showed promising results in a Phase 2a study, demonstrating an 88% reduction in Annualized Bleeding Rate (ABR). The company also plans to release two-year follow-up data from the Phase 2a study in 4Q 2022, emphasizing the need for innovative treatment options.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced positive non-clinical pharmacokinetic and safety data for LB101, its first LockBody® candidate targeting solid tumors. The study showed systemic delivery of high doses of LB101 without hematological toxicity in non-human primates, indicating an improved therapeutic index and enhanced anti-tumor activity. The company plans to submit an Investigational New Drug (IND) application by late 2022, with management discussing the findings at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced participation in key investor conferences in September 2022. Notably, they will feature in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, with a fireside chat at 8:45 AM ET in New York City. Following this, they will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 1:30 PM ET. Lastly, they will engage in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on September 28, 2022, at 11:30 AM ET. Live webcasts will be available on their website.
Centessa Pharmaceuticals (Nasdaq: CNTA) reported its Q2 2022 results, highlighting strong cash reserves of $484.2 million to fund operations into 2026. The firm plans to initiate registrational studies for SerpinPC in Hemophilia B by the end of 2022 and expects multiple clinical readouts across its pipeline over the next two years. However, it announced the discontinuation of ZF874 for Alpha-1 Antitrypsin Deficiency due to adverse events in early trials, concluding it would not achieve the desired profile.
Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs. This leadership addition aligns with the company's initiative to advance its SerpinPC program in Hemophilia B into registrational studies this year. Dr. Rotman brings extensive experience from previous regulatory roles in various pharmaceutical companies. Centessa aims to deliver impactful medicines across rare diseases and immuno-oncology, supported by a robust R&D innovation engine.
Spotlight Therapeutics has appointed Antoine Yver, M.D., M.Sc., to its Board of Directors, enhancing its leadership with over 30 years of experience in drug development. Dr. Yver is recognized for his influential role in bringing significant cancer treatments like Enhertu, Tagrisso, and Lynparza to market. This strategic move aligns with Spotlight's mission to advance its TAGE platform for gene editing therapies aimed at various diseases. The company's growth trajectory is expected to benefit from Dr. Yver's expertise in oncology and immunology.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced the appointment of Mathias Hukkelhoven, Ph.D., to its Board of Directors, effective July 1, 2022. Hukkelhoven, with extensive experience in global regulatory and drug development, previously held leadership roles at Bristol Myers Squibb and Novartis. His expertise is expected to enhance Centessa's efforts in advancing its rare disease and immuno-oncology programs. Additionally, Aaron Kantoff resigned from the Board but will remain as an advisor. This leadership transition comes at a strategic time as the company aims to fulfill unmet medical needs.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced participation in two upcoming investor conferences. The first is the Jefferies Healthcare Conference, scheduled for June 9, 2022, featuring a fireside chat webcast at 4:30 PM ET. The second is the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, with a fireside chat at 8:00 AM PT / 11:00 AM ET. Live webcasts and archived recordings will be accessible in the investor relations section of the Centessa website.
FAQ
What is the current stock price of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
What is the market cap of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
What does Centessa Pharmaceuticals specialize in?
Where is Centessa Pharmaceuticals headquartered?
What is SerpinPC?
What stage is LB101 in?
What is the focus of ORX750?
Has SerpinPC received any special designations?
What kind of development model does Centessa Pharmaceuticals use?
What other programs are in Centessa's pipeline?
What recent achievements has Centessa Pharmaceuticals made?
How can I find more information about Centessa Pharmaceuticals?
